RIGHT TO TRY ACT

Amendments

Enact (H.R. 5247): consideration (H. Res. 787), H1709 [20MR]

Enact (S. 204): consideration (H. Res. 905), H4300 [22MY]

Bills and resolutions

Enact (H.R. 5247): consideration (see H. Res. 787), H1697 [19MR]

Enact (S. 204): consideration (see H. Res. 905), H4283 [21MY]

Letters

Provisions: Andrew McFadyen, Isaac Foundation, H1740 [21MR]

——— several organizations, H4358 [22MY]

Lists

Organizations opposed to H.R. 5247, provisions, H1525 [13MR], H1742 [21MR]

Motions

Enact (H.R. 5247), H1746 [21MR]

Enact (S. 204), H4363 [22MY]

Remarks in House

Drugs: require FDA guidance relative to investigational drug use by eligible patients, provide liability protection for facilitators of investigational treatments and increase transparency of number of such treatments, H1747, H1748 [21MR]

Enact (H.R. 878), H685 [30JA], H1647 [15MR]

Enact (H.R. 5247), H1521–H1529, H1530 [13MR], H1738–H1750 [21MR]

——— consideration (H. Res. 787), H1704–H1712 [20MR]

——— motion to recommit, H1747, H1748 [21MR]

Enact (S. 204), H485 [18JA], H4355–H4366 [22MY], H4682 [23MY], E751 [29MY]

——— consideration (H. Res. 905), H4292–H4301 [22MY]

——— motion to recommit, H4364, H4365 [22MY]

FDA: improve expanded access program to allow patients access to experimental life-saving drugs, H4364, H4365 [22MY]

Remarks in Senate

Donnelly, Senator: appreciation of opportunity to serve, S7406–S7409 [11DE]

Enact (H.R. 5247), S1981, S1982 [22MR], S1994 [9AP]

——— unanimous-consent request, S1981 [22MR]

Reports filed

Consideration of H.R. 5247, Provisions: Committee on Rules (House) (H. Res. 787) (H. Rept. 115–613), H1697 [19MR]

Consideration of S. 204, Provisions: Committee on Rules (House) (H. Res. 905) (H. Rept. 115–698), H4283 [21MY]

Statements

Provisions: Senator Johnson, H4360 [22MY]

Texts of

H. Res. 787, consideration of H.R. 5247, provisions, H1704 [20MR]

H. Res. 905, consideration of S. 204, provisions, H4292 [22MY]

H.R. 5247, provisions, H1521 [13MR], H1738 [21MR]

S. 204, provisions, H4355 [22MY]